GRTX

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Galera Therapeutics (GRTX – Research Report), with a price target of $10.00. The company's shares closed last Wednesday at $1.70, close to its 52-week low of $1.15. According to TipRanks.com, Selvaraju has 0 stars on 0-5 stars ranking scale with an average return of -45.1% and a 7.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Santhera Pharmaceuticals Holding AG, Inovio Pharmaceuticals, and Aquestive Therapeutics. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Galera Therapeutics with a $10.00 average price target.
https://www.tipranks.com/news/blurbs/h-c-wainwright-thinks-galera-therapeutics-stock-is-going-to-recover-3?utm_source=advfn.com&utm_medium=referral